Back to treatments

Semaglutide / GLP-1 Weight Loss

GLP-1 therapies are widely used to support medical weight management by regulating appetite and metabolic functions. This approach is commonly used as a medically guided weight loss treatment, helping patients achieve sustainable, clinically supported results under the supervision of experienced providers. 

Find a Provider

Overview

What is GLP-1 Therapy?

GLP-1 therapy refers to a class of medications that mimic glucagon-like peptide-1, a hormone that regulates appetite, slows gastric emptying, and supports insulin response. Medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are prescribed to support weight loss and metabolic health under clinical supervision.

Clinical studies show that GLP-1 therapy can lead to meaningful, sustained weight reduction when combined with lifestyle support. For example, semaglutide has demonstrated an average weight loss of approximately 15 percent, while tirzepatide has shown results exceeding 20 percent in some patients. Treatment is individualized and requires ongoing monitoring to ensure safety and effectiveness.

 

Find a Provider

Cost of GLP-1 Therapy (Ozempic, Wegovy, Mounjaro, Zepbound)

The cost of GLP-1 therapy varies based on medication type, dosing, insurance coverage, and provider oversight. Monthly prescriptions and follow-up care contribute to the overall cost. 

Up to 15–22% average weight loss in clinical trials

Success rates

$900/month

Average cost (USD)

Millions of prescriptions worldwide

Procedures performed annually

Low when medically supervised

Complication rate

Average cost (USD)

$900/month

Cost Range (USD)

$300 – $1,500/month

Costs reflect both medication access and ongoing clinical management. Because GLP-1 therapy is typically long-term, financial planning and provider guidance are important parts of treatment. 

Pros and Cons of Getting GLP-1 Therapy

Pros

  • Appetite control
  • Weight reduction
  • Blood sugar support
  • Non-surgical
  • Clinically studied
  • Gradual results

Cons

  • Ongoing treatment
  • Monthly cost
  • GI side effects
  • Not universal
  • Requires monitoring
  • Results require maintenance

 

How it Works

GLP-1 therapy works by activating receptors in the brain and digestive system that influence hunger, fullness, and blood sugar regulation. By slowing gastric emptying and signaling satiety earlier in a meal, these medications help patients reduce caloric intake without the constant effort of restriction. Treatment follows a structured protocol under medical supervision, with dosing carefully titrated over time to balance results with tolerability.

What it Treats

GLP-1 therapy treats obesity, overweight conditions, and metabolic dysfunction by regulating appetite, improving insulin sensitivity, and reducing caloric intake through hormonal pathways 

Procedure Time

Treatment involves weekly or daily self-administered injections, with initial consultations lasting 30 to 60 minutes and ongoing follow-up visits as needed. 

Eligibility

Candidates include adults with obesity or weight-related conditions. A medical evaluation determines eligibility based on health history, medications, and metabolic risk factors. 

Recovery & Downtime

There is no procedural downtime. Patients continue daily activities while adjusting to treatment, with mild side effects typically improving over time. 

What to Expect Before, During, and After GLP-1 Therapy

Before GLP-1 Therapy

A consultation includes a review of medical history, current medications, and weight goals. Providers explain dosing, expected timelines, and potential side effects to support informed decision-making.

During GLP-1 Therapy

Patients follow a structured dosing schedule, typically starting at a lower dose and increasing gradually. Regular follow-ups assess progress, tolerance, and metabolic response.

After GLP-1 Therapy

Long-term outcomes depend on adherence and lifestyle support. Some patients continue therapy, while others transition off under supervision with a focus on maintaining results.

Potential Risks and Side Effects from GLP-1 Therapy

Gastrointestinal symptoms

Nausea, vomiting, and diarrhea are the most common side effects, particularly during dose escalation. These symptoms are usually temporary and improve with time.

Metabolic considerations

Changes in blood sugar levels require monitoring, especially for patients managing diabetes or using other glucose-lowering medications.

Rare complications

Rare risks may include pancreatitis or gallbladder issues. A licensed provider evaluates individual risk and monitors for symptoms throughout treatment.

Frequently Asked Questions

Most patients notice appetite changes within the first few weeks, with measurable weight loss developing over several months. Full results depend on consistency and individualized treatment plans. 

GLP-1 therapy is considered safe when prescribed and monitored by a licensed provider. Clinical trials and regulatory approvals support its use for weight and metabolic management. 

Weight changes after discontinuation depend on lifestyle habits and metabolic factors. Providers often guide patients through structured maintenance plans to support long-term outcomes. 

Patients with certain endocrine conditions, medication interactions, or contraindications may not be eligible. A consultation is required to determine safety and suitability. 

No. GLP-1 therapy is designed to support, not replace, healthy nutrition and physical activity. Long-term success depends on a comprehensive approach to lifestyle and care. 

Sources & Studies

The following references provide clinical evidence and safety information on  GLP-1 Therapy (Ozempic, Wegovy, Mounjaro, Zepbound):

(NEJM) - Semaglutide Weight Loss Clinical Trial

Randomized clinical trial demonstrating approximately 15% average weight loss with semaglutide, supporting its effectiveness for long-term weight management.

(NELM) - Tirzepatide Weight Loss Outcomes

Large-scale clinical trial showing up to 20% weight reduction with tirzepatide, along with significant improvements in metabolic health markers.

FDA - Approval for Wegovy (Semaglutide) for Chronic Weight Management

FDA approval based on clinical evidence confirming safety and efficacy of semaglutide for chronic weight management in adults with obesity.

FDA - Approval for Zepbound (Tirzepatide) for Weight Management

Regulatory approval of tirzepatide for weight management, supported by clinical trial data demonstrating significant weight loss outcomes.

American Diabetes Association - Guidelines on GLP-1 Therapies

Evidence-based clinical guidelines recommending GLP-1 receptor agonists for weight and glucose management as part of modern metabolic care.

All sources reviewed for clinical accuracy and relevance.

Locate a Certified Clinic for Semaglutide / GLP-1 Weight Loss

Discover trusted, world-class clinics verified for safety, expertise, and patient experience.

Explore Directory